Will This Analyst Upgrade Help Allergan (AGN) Stock Today?

NEW YORK (TheStreet) -- UBS upgraded Allergan  (AGN) to "buy" from "neutral" and set a $200 price target. The firm said the company plans to see more sales growth while they consider a deal with Valeant (VRX).

Leerink Swann also increased its price target on Allergan to $184, increased its estimates and set a "market perform" rating. The firm said the company is aggressively cutting costs.

The stock closed at $171.14 on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AGN Chart AGN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)